USPTO Patent Application: Cannabinoid Delivery Capsules
Summary
The USPTO has published a new patent application (US20260083756A1) from Fertin Pharma A/S for capsules designed for peroral cannabinoid delivery. The application details formulations using self-emulsifying drug delivery systems (SEDDS) with specific surfactant and cannabinoid content.
What changed
This document is a USPTO patent application (US20260083756A1) filed by Fertin Pharma A/S on September 20, 2024. It describes a novel capsule formulation for the oral delivery of cannabinoids. The formulation includes self-emulsifying drug delivery systems (SEDDS) with at least 20% surfactants containing a polyethylene glycol (PEG) moiety, and at least 10% cannabinoids (isolated or synthetic).
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signals potential future developments in cannabinoid-based drug delivery systems. Companies involved in pharmaceutical manufacturing, particularly those working with cannabinoids or novel drug delivery technologies, should be aware of this filing as it may impact future product development and intellectual property landscapes.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Capsules With Self-Emulsifying Drug Delivery Systems
Application US20260083756A1 Kind: A1 Mar 26, 2026
Assignee
Fertin Pharma A/S
Inventors
Sanne Skov Jensen, Gitte Nykjær Nikolajsen, Benjamin Bugge Wahlqvist
Abstract
A capsule for peroral delivery of cannabinoids includes a cannabinoid formulation contained in a hard shell or soft shell of the capsule. The formulates include: one or more self-emulsifying drug delivery systems (SEDDS) including one or more surfactants having a chemical structure that includes a polyethylene glycol (PEG) moiety in an amount of at least 20% by weight of the one or more SEDDS; and one or more cannabinoids including one or more isolated or synthetic cannabinoids in an amount of at least 10% by weight of the formulation.
CPC Classifications
A61K 31/658 A61K 9/4858 A61K 9/4866
Filing Date
2024-09-20
Application No.
18891015
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.